

# ENS-CCA / Precision-BTC-Network Joint Meeting

June 11-12, 2026

**Conference Directors** Luke Boulter / Rocio Macias / Chiara Braconi  
**Local Organizer** Konstantinos Athanasopoulos

Day 1	Academia-Pharma Interaction		June 11th 2026
TIME (EEST)	TITLE	SPEAKER	
8:00-8:45	Registration, badge & material delivery		
8:45-9:00	Welcome words	Konstantinos Athanasopoulos (Greece)	
9:00 - 9:15	ENSCCA 10 Years Reflection	Luke Boulter (UK)	
9:15 - 9:30	COST Update/Overview	Rocio Macias (Spain)	
<b>9:30 - 10:45 SESSION 1: TRANSLATION INTO CLINICAL DEVELOPMENT: ROLE OF AI IN BIOMARKERS &amp; DIAGNOSTICS</b>			
<i>Moderators:</i>		<i>Alejandro Forner (Spain) &amp; Tim Kendall (UK)</i>	
9:30 - 9:40	Challenges in diagnostics of biliary tract cancers	Pedro Rodrigues (Spain)	
9:40 - 10:00	Panel discussion	<i>With the addition of:</i> Jesus Banales (Spain), Stephen Rossi (Spain)	
<i>Moderators:</i>		<i>Anna Saborowski (Germany) &amp; Victor Moreno (Spain)</i>	
10:00 - 10:10	Implementation of pathology and molecular biomarkers into clinical practice	Benjamin Goeppert (Germany)	
10:10 - 10:20	Example of a biomarker-driven therapeutics: what is the challenge and how can academia help?	Brian Lockhart (Servier)	
10:20 - 10:45	Panel discussion	<i>With the addition of:</i> Stacie Lindsey (CCF), Benjamin Goeppert (Germany)	
<b>10:45 - 11:30 Coffee Break</b>			
<b>11:30-13:00 SESSION 2: PATIENT INVOLVEMENT INTO EARLY TRIALS</b>			
<i>Moderators:</i>		<i>Angela Lamarca (Spain) &amp; John Bridgewater (UK)</i>	
11:30-11:40	Challenges of rare cancers in clinical trials	Arndt Vogel (Germany)	
11:40-11:50	Challenges of rare cancers in clinical trials: insights from academic collaboration in BTC & DMG	Katherine Baria (Jazz Pharmaceuticals)	
11:50-12:00	Phase 1 trials - Patient views: how can patient advocacy groups impact on trial design?	Juan Valle (CCF)	
12:10-12:20	Phase 1 trial success: IDH1 in BTC	Lorenza Rimassa (ILCA member, Italy)	
12:20-12:30	How to make academic trials with on-patent drugs successful	John Bridgewater (UK)	
12:30 - 13:00	Panel discussion	<i>With the addition of:</i> Helen Morement (AMMF), Matteo Fassan (Italy)	
<b>13:00 - 14:30 Lunch Break</b>			
<b>14:30 - 15:30 ORAL ABSTRACTS</b>			
<i>Moderators:</i>		<i>Rui Castro (Portugal) &amp; Mairead McNamara (UK)</i>	
<b>15:30 - 16:15 KEYNOTE TALK</b>			
	Introduction	Chiara Braconi (UK)	
	Therapeutic development: directions from basic research	Tim Greten (USA)	
<b>16:15 - 17:25 SESSION 3: DRUG DEVELOPMENT: NEW TARGETS &amp; COMPOUNDS TO CLINIC</b>			
<i>Moderators:</i>		<i>Teresa Macarulla (Spain) &amp; Tim Greten (USA)</i>	
16:15-16:25	Approach from big pharma: what are you looking for when you invest in a new compound?	Caleb Briggs (AstraZeneca)	
16:25-16:35	Approach from smaller biotech: the evolution from academia to industry	Flavia Scialpi (Trogenix, UK)	
16:35-16:45	ADCs: where are we going?	Victor Moreno (Spain)	
16:45-16:55	Drug development in a patients' niche: how to collaborate between industry and academia?	Kristin Ryan (Elevar Therapeutics, USA)	
16:55-17:05	Supporting devices for drug discovery: next-generation preclinical platforms for CCA research	Ana Lleo (Italy)	
17:05 - 17:25	Panel discussion	<i>With the addition of:</i> Tian Tian (Spain)	
<b>17:25 - 18:15 POSTER TOUR</b>			
<i>Moderators:</i>		<i>Konstantinos Athanasopoulos (Greece), Pilar Acedo (UK) &amp; Jerzy Kotlinowski (Poland)</i>	
<b>20:00 Joint Dinner</b>			

Day 2	Precision-BTC Network Annual Conference		June 12th 2026
TIME	TITLE	SPEAKER	
8:00 - 8:30	Registration, badge & material delivery		
8:30 - 9:30	SESSION 1: WG1 - IDENTIFICATION OF EPIDEMIOLOGICAL HETEROGENEITY IN EUROPE		
	<i>Moderators:</i> 10 minute presentation + 5 minute discussion	<i>Marcin Krawczyk (Poland) &amp; Lewis Roberts (USA)</i>	
8:30 - 8:45	Stromal network remodelling shapes immune cell organisation in lymph nodes and tumors	Veronika Lukacs-Kornek (Germany)	
8:45 - 9:00	GLOBAL-BTC registry: expanding the understanding of cancer across the biliary tract	Laura Izquierdo-Sanchez (Spain)	
9:00 - 9:15	A machine learning-powered tool to characterize CCA prognosis	Lorenzo Manganaro (Italy)	
9:15 - 9:30	Personalized prevention & surveillance for cholangiocarcinoma in primary sclerosing cholangitis	Shahid Khan (UK)	
09:30 - 10:30	SESSION 2: WG2 - PERSONALISED EARLY DETECTION OF BTC		
	<i>Moderators:</i> 10 minute presentation + 5 minute discussion	<i>Guido Carpino (Italy) &amp; Stephanie Roessler (Germany)</i>	
9:30 - 9:45	Molecular diagnostic solutions for detection of malignant biliary strictures	Michael Dill (Germany)	
9:45 - 10:00	Novel blood metabolomic tests for the diagnosis of primary sclerosing cholangitis and associated CCA	Ainhua Lapitz (Spain)	
10:00 - 10:15	Proteomic profiling of circulating early detection biomarkers in PSC and CCA	Rebeca Correa González (UK)	
10:15 - 10:30	Extracellular matrix remodeling links PSC to cholangiocarcinoma in a sex-dependent manner	Camilla Venturin (Italy)	
10:30-11:00	Coffee Break & Group Photo		
11:00 - 12:00	SESSION 3: WG3 - PERSONALISATION OF TREATMENT FOR PATIENTS WITH BTC		
	<i>Moderators:</i> 10 minute presentation + 5 minute discussion	<i>Anna Saborowski (Germany) &amp; Elene Mariamidze (Georgia)</i>	
11:00 - 11:15	Biomarker of adjuvant chemotherapy: data from the BILCAP trial	Chiara Braconi (UK)	
11:15 - 11:30	Insights from real world data from the international community: strategizing the chemoimmunotherapy	Andrea Casadei-Gardini (Italy)	
11:30 - 11:45	Route of diagnosis, onset of symptoms and potential areas of improvement in BTC	Andrea Martirena (Spain)	
12:00 - 13:00	SESSION 4: WG4 - PATIENT-CENTRIC SUPPORT MANAGEMENT		
	<i>Moderators:</i> 10 minute presentation + 5 minute discussion	<i>Ana Lleo (Italy) &amp; Mohamed Bouattour (France)</i>	
12:00 - 12:15	The role of nurse in Europe	Gemma Iserte (Spain)	
12:15 - 12:30	Precision-BTC and EORTC: ongoing collaboration	Antonella Cammarota (Italy)	
12:30 - 12:45	Cholangiocarcinoma patients at the heart of policy	Helen Morement (AMMF)	
12:45 - 13:00	Shining light on hidden cancers: BTC in Europe	Elisabeth Baucells (ATUVIBI)	
13:00-14:30	Lunch Break		
14:30-15:30	SESSION 5: WG5 - ARTIFICIAL INTELLIGENCE		
	<i>Moderator:</i> 10 minute presentation + 5 minute discussion	<i>Jesper B Andersen (Denmark) &amp; Ghada Nouairia (Sweden)</i>	
14:30 - 14:45	Update on the molecular registry	Colm O'Rourke (Denmark)	
14:45 - 15:00	AI in iCCA: from diagnosis to treatment decisions	Stefano Caruso (France)	
15:00 - 15:15	Genome-wide methylation profiling from BTCs and PSC using blood DNA provides diagnostic tools and biological insights	Ghada Nouairia (Sweden)	
15:30-16:30	SESSION 6: WG6 - DRUG DEVELOPMENT USING PRECLINICAL MODELS		
	<i>Moderators:</i> 10 minute presentation + 5 minute discussion	<i>Marta Afonso (Portugal) &amp; Attila Hunyadi (Hungary)</i>	
15:30 - 15:45	Targeting the stroma	Silvia Affo (Spain)	
15:45 - 16:00	Drug discovery with patients derived organoids	Daniela Sia (Mount Sinai, USA)	
16:00 - 16:15	Early neoplastic transition states as targets for precision prevention	Ed Jarman (UK)	
16:15 - 16:30	Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma	Konstantina Morali (Spain)	
16:30 - 16:35	Closing remarks and farewell		